- Nano cap Atossa Genetics (NASDAQ:ATOS) is up 10% after hours on robust volume after it announced new Phase 1 data on breast cancer candidate endoxifen.
- The median time for orally administered endoxifen to reach steady-state serum levels was seven days, substantially quicker than oral tamoxifen, which takes 50 - 200 days (both drugs once/day).
- Median time to reach maximum serum levels was four-to-eight hours (dose dependent) for endoxifen. The 4 mg daily dose produced a maximum serum level in the this time frame above the generally accepted threshold for a therapeutic effect on estrogen-dependent breast cancer.
- CEO Steve Quay, Ph.D., M.D., says, “These additional findings are important for several reasons. Breast cancer patients do not typically want to wait weeks or even months for the current standard of care, oral tamoxifen, to take effect. Our study data indicates that our proprietary oral Endoxifen reaches a steady-state in about 7 days, while the literature indicates that it can take 50-200 days for tamoxifen to reach a steady-state – keeping in mind that a breast cancer tumor can double in size in as little as 29 days. Not only does it take up to several months for oral tamoxifen to take effect, oral tamoxifen also does not benefit up to 50% of patients, partly because many patients cannot metabolize tamoxifen. For these reasons, we believe our oral Endoxifen may reduce the incidence of this deadly disease and fundamentally change the paradigm for breast cancer treatment,” added Dr. Quay.
- Previously: Atossa Genetics to host conference call tomorrow on Phase 1 endoxifen data; shares ahead 17% premarket (Jan. 31)
- Now read: Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/1/2018)
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Original article